There are a ~dozen of studies on dasatinib (anti-cancer drug) + quercetin (senolytic) for curing osteoarthritis in humans, improving heart tissue etc, with dasatinib used as a senolytic. Navitoclax (anti-cancer drug) also used as senolytic in some studies.
In this context it seems that adverse effects from senolytics may be more pronounced in cancer-prone, in younger age or if taking them continuously (not like 5 days per month or so letting some senescent cells to emerge). Yet Sinclair's new venture TallyHealth, for example, are selling a 5 in one capsule, containing apart from other stuff 500 mg quercetin and 100 mg fisetin (senolytics) with an expectation of daily intake. And his 80y old dad is taking senolytics daily with still no cancer.